Can Liver Cancer Patients Take Fucoidan to Support Chemotherapy?
How Oligo-Fucoidan Inhibits Tumors, Improves Fatty Liver, and Modulates Immunity – Providing Comprehensive Adjuvant Support for Liver Cancer Patients
Free cancer support
Fucoidan is a natural polysaccharide extracted from brown seaweed (such as kelp, wakame, and giant kelp). It is rich in fucose and sulfate groups, and can modulate immunity, reduce inflammation, and promote apoptosis. Recent studies have further confirmed its inhibitory effects on various cancer cells, including breast cancer, lung cancer, and liver cancer.
However, conventional fucoidan has a large molecular weight and low absorption efficiency. Taiwanese research teams therefore developed oligo-fucoidan with a molecular weight of only about 500 Daltons, enabling much more effective intestinal absorption. Once in the bloodstream, it acts at the cellular level, demonstrating stronger physiological activity and anti-tumor potential.
For liver cancer patients, the value of this natural compound lies in its ability not only to help suppress cancer cell growth but also to potentially improve liver metabolism and immune response — offering a completely new direction in adjuvant therapy.
What is Oligo-Fucoidan?
International Collaborative Study: Suppressing Liver Tumor Formation
In 2021, Dr. Yao Qunyan from the Department of Gastroenterology, Zhongshan Hospital, Fudan University (Shanghai), published a study showing that oral oligo-fucoidan effectively inhibited tumor volume in a mouse model of liver cancer by regulating gene expression to reduce cancer cell proliferation and promote apoptosis.
The study found that oligo-fucoidan induced overexpression of the long non-coding RNA LINC00261, which in turn disrupted proliferative signalling in cancer cells, significantly slowing tumor growth.
Published in the international journal Cancer Science, this breakthrough is regarded as a major advance in molecular therapy for liver cancer, demonstrating that fucoidan is not merely a nutritional supplement but a natural compound with clear gene-level regulatory effects.
Associate Investigator Yu Chiu-Hua from the Institute of Molecular and Genomic Medicine at Taiwan’s National Health Research Institutes used a zebrafish model to explore the effects of oligo-fucoidan on liver health. Results showed that zebrafish fed oligo-fucoidan exhibited markedly reduced hepatic fat accumulation and fibrosis, upregulated antiviral gene expression, activated immune responses, and overall improved liver function.
The team further elucidated the molecular mechanism, revealing involvement of the ASGR/STAT3/HNF4A signalling axis. Oligo-fucoidan increases expression of the HNF4A P1 isoform in hepatocytes, enhancing liver metabolic capacity while reducing oxidative stress and inflammatory responses, ultimately achieving prevention of fatty liver and inhibition of liver cancer formation.
Published in international journals such as Marine Drugs, this breakthrough not only opens new thinking in preventive adjuvant therapy but also suggests that oligo-fucoidan may become an important nutritional adjuvant for high-risk groups (such as patients with chronic hepatitis or fatty liver) in preventing liver cancer in the future.
Taiwan NHRI Study: Protective Mechanism from Fatty Liver to Liver Cancer
Taiwan Clinical Study: Reducing Liver Cancer Metastasis and Recurrence Risk
Another major study by a Taiwanese research team showed that oligo-fucoidan effectively inhibits liver cancer cell metastasis by regulating the microRNA-29b and DNMT3B–MTSS1 signalling pathways.
In liver cancer cell line experiments, oligo-fucoidan increased miR-29b expression, leading to downregulation of the methylation enzyme DNMT3B, which in turn restored function of the tumor suppressor gene MTSS1. This process simultaneously blocked the epithelial-mesenchymal transition (EMT) — the shift that makes cancer cells highly invasive — thereby reducing invasion and metastasis.
Furthermore, the study found that oligo-fucoidan modulates long non-coding RNA (lncRNA) expression in liver cancer cells, inducing spontaneous apoptosis and thereby lowering recurrence risk.
For patients who have undergone surgery or targeted therapy, this adjuvant mechanism provides a second layer of protection, helping prevent disease relapse.
Improving Fatty Liver and Boosting Immunity
Many liver cancer patients also suffer from concurrent fatty liver or metabolic disorders. Oligo-fucoidan, with its antioxidant and anti-inflammatory properties, can reduce hepatic fat accumulation and promote hepatocyte regeneration. Studies show it enhances the activity of macrophages and natural killer (NK) cells, enabling the body to more effectively eliminate damaged cells and viruses.
For patients, this means it not only aids in fighting cancer but also improves the overall liver environment, reducing the burden and fatigue caused by treatment.
Physician Recommendation: Adjuvant, Not a Replacement
Although numerous studies currently support the potential adjuvant effects of oligo-fucoidan in liver cancer treatment, physicians still emphasize that it is not an anti-cancer drug — it is a nutritional supplement that can be used alongside existing treatments (such as chemotherapy, targeted therapy, or immunotherapy).
Patients who wish to use it should consult their attending physician to confirm dosage and safety. Only choose oligo-fucoidan products with clinical research backing, clearly defined molecular weight, and guaranteed safe sourcing to ensure efficacy and safety.
Conclusion: Finding Nature’s Power Through Science
Liver cancer management relies not only on drugs but also on strengthening immunity and repair capacity. Oligo-fucoidan, a natural substance derived from the ocean, is demonstrating the remarkable potential of combining science and nature.
From inhibiting tumor growth and regulating gene expression to improving fatty liver and the immune environment, it does more than help patients endure treatment — it represents a new philosophy of life: facing illness in a healthier way and moving toward recovery.
Want to know how to choose the most suitable adjuvant therapy for cancer?
Contact our professional team now
References
- Yao, Q. Y., & Zhang, Y. H. (2021). Fucoidan inhibits the progression of hepatocellular carcinoma via causing lncRNA LINC00261 overexpression. Cancer Science, 112(4), 1506–1517.
- Yu, C. H., & Lin, C. H. (2020). Low-molecular-weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling. Marine Drugs, 18(12), 601–614.
- Yu, C. H., & Lin, C. H. (2020). Transcriptomically revealed oligo-fucoidan enhances the immune system and protects hepatocytes via the ASGR/STAT3/HNF4A axis. Journal of Cellular Biochemistry, 121(9), 4221–4233.
- Lai, J. M., & Tsai, Y. P. (2019). Fucoidan elevates microRNA-29b to regulate DNMT3B–MTSS1 axis and inhibit EMT in human hepatocellular carcinoma cells. Marine Drugs, 17(8), 457–469.
- Lai, J. M., & Tsai, Y. P. (2019). The anti-tumor activity of brown seaweed oligo-fucoidan via lncRNA expression modulation in HepG2 cells. International Journal of Biological Macromolecules, 133, 1276–1285.